This technology is a suite of hydrogen sulfide (H2S) prodrugs that has broad applicability for decreasing toxicity during the treatment of inflammation using NSAIDs. In vivo studies have demonstrated reduction of gastrointestinal ulcers, kidney toxicity, and liver toxicity during NSAID use. In separate in vivo studies, these technologies reduced brain tissue damage in ischemic stroke. These H2S prodrugs release H2S in response to biologically relevant triggers. In contrast to H2S prodrugs in development, these technologies offer controlled, tunable release and improved biocompatibility. This technology capitalizes on the role of H2S as a gasotransmitter and naturally occurring signaling molecule. These technologies could also be used as research tools.
Patent Status
2024-006 compounds: Pending in U.S., EP, China: WO2025042979A1 - Hydrogen sulfide prodrugs and uses thereof - Google Patents
2015-07 compounds: Issued in U.S., UK, France, Germany, China, Hong Kong: US10689335B2 - Hydrogen sulfide precursors and conjugates thereof - Google Patents
Publications
2024-006: A Highly Atom-Efficient Prodrug Approach to Generate Synergy between H2S and Nonsteroidal Anti-inflammatory Drugs and Improve Safety | Journal of Medicinal Chemistry